Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).
Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.
In obese patients without gallstones, a 6-month treatment course of ursodeoxycholic acid (UDCA) following bariatric surgery may reduce their likelihood of developing symptomatic gallstones, according to findings of the UPGRADE trial from The Netherlands presented at DDW 2021.
Results of a single-centre study in the UK have suggested that patients receiving systemic anticancer therapy for gastrointestinal (GI) cancers could continue their treatment during the COVID-19 pandemic.